|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-9-23
|
|
pubmed:abstractText |
A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial assessed the impact of treatment on quality of life (QoL).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:BenassiGG,
pubmed-author:BokemeyerCC,
pubmed-author:CupissolDD,
pubmed-author:CurranDD,
pubmed-author:De RaucourtDD,
pubmed-author:DelordJ-PJP,
pubmed-author:GrossAA,
pubmed-author:HittRR,
pubmed-author:KaweckiAA,
pubmed-author:KienzerHH,
pubmed-author:KoralewskiPP,
pubmed-author:MesíaRR,
pubmed-author:RiveraFF,
pubmed-author:RotterHH,
pubmed-author:VermorkenJ BJB
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1967-73
|
|
pubmed:meshHeading |
pubmed-meshheading:20335368-Adult,
pubmed-meshheading:20335368-Aged,
pubmed-meshheading:20335368-Aged, 80 and over,
pubmed-meshheading:20335368-Antibodies, Monoclonal,
pubmed-meshheading:20335368-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20335368-Carboplatin,
pubmed-meshheading:20335368-Carcinoma, Squamous Cell,
pubmed-meshheading:20335368-Cisplatin,
pubmed-meshheading:20335368-Female,
pubmed-meshheading:20335368-Fluorouracil,
pubmed-meshheading:20335368-Head and Neck Neoplasms,
pubmed-meshheading:20335368-Humans,
pubmed-meshheading:20335368-Lymphatic Metastasis,
pubmed-meshheading:20335368-Male,
pubmed-meshheading:20335368-Middle Aged,
pubmed-meshheading:20335368-Neoplasm Recurrence, Local,
pubmed-meshheading:20335368-Neoplasm Staging,
pubmed-meshheading:20335368-Quality of Life,
pubmed-meshheading:20335368-Survival Rate,
pubmed-meshheading:20335368-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
|
pubmed:affiliation |
Department of Medical Oncology, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
